|
1
|
Global Burden of Disease Cancer
Collaboration, . Fitzmaurice C, Dicker D, Pain A, Hamavid H,
Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, et
al: The global burden of cancer 2013. JAMA Oncol. 1:505–527. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yokota T, Igaki H, Kato K, Tsubosa Y,
Mizusawa J, Katayama H, Nakamura K, Fukuda H and Kitagawa Y:
Accuracy of preoperative diagnosis of lymph node metastasis for
thoracic esophageal cancer patients from JCOG9907 trial. Int J Clin
Oncol. 21:283–288. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: Defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mohr AM and Mott JL: Overview of microRNA
biology. Semin Liver Dis. 35:3–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vienberg S, Geiger J, Madsen S and
Dalgaard LT: MicroRNAs in metabolism. Acta Physiol (Oxf).
219:346–361. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Reddy KB: MicroRNA (miRNA) in cancer.
Cancer Cell Int. 15:382015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: Diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kiselev FL: MicroRNA and cancer. Mol Biol
(Mosk). 48:232–242. 2014.(In Russian). PubMed/NCBI
|
|
10
|
Mei LL, Qiu YT, Zhang B and Shi ZZ:
MicroRNAs in esophageal squamous cell carcinoma: Potential
biomarkers and therapeutic targets. Cancer Biomark. 19:1–9. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liang Y, Yang W, Zhu Y and Yuan Y:
Prognostic role of microRNA-203 in various carcinomas: Evidence
from a meta-analysis involving 13 studies. SpringerPlus.
5:15382016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chi Y, Jin Q, Liu X, Xu L, He X, Shen Y,
Zhou Q, Zhang J and Jin M: miR-203 inhibits cell proliferation,
invasion, and migration of non-small-cell lung cancer by
downregulating RGS17. Cancer Sci. 108:2366–2372. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shen J, Zhang J, Xiao M, Yang J and Zhang
N: miR-203 suppresses bladder cancer cell growth and targets
twist1. Oncol Res. 26:1155–1165. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen LZ, Ding Z, Zhang Y, He ST and Wang
XH: MiR-203 over-expression promotes prostate cancer cell apoptosis
and reduces ADM resistance. Eur Rev Med Pharmacol Sci.
22:3734–3741. 2018.PubMed/NCBI
|
|
15
|
Hezova R, Kovarikova A, Srovnal J,
Zemanova M, Harustiak T, Ehrmann J, Hajduch M, Svoboda M, Sachlova
M and Slaby O: Diagnostic and prognostic potential of miR-21,
miR-29c, miR-148 and miR-203 in adenocarcinoma and squamous cell
carcinoma of esophagus. Diagn Pathol. 10:422015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang F, Yang Z, Cao M, Xu Y, Li J, Chen
X, Gao Z, Xin J, Zhou S, Zhou Z, et al: MiR-203 suppresses tumor
growth and invasion and down-regulates MiR-21 expression through
repressing Ran in esophageal cancer. Cancer Lett. 342:121–129.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang SY, Gao F, Peng CG, Zheng CJ and Wu
MF: Hsa-miR-203 inhibits fracture healing via targeting PBOV1. Eur
Rev Med Pharmacol Sci. 22:5797–5803. 2018.PubMed/NCBI
|
|
20
|
Shi K, Qiu X, Zheng W, Yan D and Peng W:
MiR-203 regulates keloid fibroblast proliferation, invasion, and
extracellular matrix expression by targeting EGR1 and FGF2. Biomed
Pharmacother. 108:1282–1288. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pham TT, Angus SP and Johnson GL: MAP3K1:
Genomic alterations in cancer and function in promoting cell
survival or apoptosis. Genes Cancer. 4:419–426. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hagemann C and Blank JL: The ups and downs
of MEK kinase interactions. Cell Signal. 13:863–875. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bonvin C, Guillon A, van Bemmelen MX,
Gerwins P, Johnson GL and Widmann C: Role of the amino-terminal
domains of MEKKs in the activation of NF kappa B and MAPK pathways
and in the regulation of cell proliferation and apoptosis. Cell
Signal. 14:123–131. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kyriakis JM and Avruch J: Mammalian
mitogen-activated protein kinase signal transduction pathways
activated by stress and inflammation. Physiol Rev. 81:807–869.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Uhlik MT, Abell AN, Cuevas BD, Nakamura K
and Johnson GL: Wiring diagrams of MAPK regulation by MEKK1, 2, and
3. Biochem Cell Biol. 82:658–663. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lange-Carter CA, Pleiman CM, Gardner AM,
Blumer KJ and Johnson GL: A divergence in the MAP kinase regulatory
network defined by MEK kinase and Raf. Science. 260:315–319. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu C, Wang S, Zhu S, Wang H, Gu J, Gui Z,
Jing J, Hou X and Shao Y: MAP3K1-targeting therapeutic artificial
miRNA suppresses the growth and invasion of breast cancer in vivo
and in vitro. SpringerPlus. 5:112016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hirano T, Shino Y, Saito T, Komoda F,
Okutomi Y, Takeda A, Ishihara T, Yamaguchi T, Saisho H and
Shirasawa H: Dominant negative MEKK1 inhibits survival of
pancreatic cancer cells. Oncogene. 21:5923–5928. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Su F, Li H, Yan C, Jia B, Zhang Y and Chen
X: Depleting MEKK1 expression inhibits the ability of invasion and
migration of human pancreatic cancer cells. J Cancer Res Clin
Oncol. 135:1655–1663. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bian D, Su S, Mahanivong C, Cheng RK, Han
Q, Pan ZK, Sun P and Huang S: Lysophosphatidic acid stimulates
ovarian cancer cell migration via a ras-MEK kinase 1 pathway.
Cancer Res. 64:4209–4217. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zang WQ, Yang X, Wang T, Wang YY, Du YW,
Chen XN, Li M and Zhao GQ: MiR-451 inhibits proliferation of
esophageal carcinoma cell line EC9706 by targeting CDKN2D and
MAP3K1. World J Gastroenterol. 21:5867–5876. 2015. View Article : Google Scholar : PubMed/NCBI
|
